Understand the source comparison
DSIP vs Ipamorelin: Research Protocol Comparison
Primary Mechanism GABA-A receptor potentiation + delta-opioid agonism GHS-R1a agonism → pituitary GH release Distinct receptor targets. No overlap Peak Effect Timing 30–90 min (sleep onset facilitation) 20–30 min (peak plasma GH) DSIP = acute CNS; Ipamorelin =
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- GABA-A receptor potentiation + delta-opioid agonism
- GHS-R1a agonism → pituitary GH release
- Distinct receptor targets. No overlap
- Peak Effect Timing
- 30–90 min (sleep onset facilitation)
- 20–30 min (peak plasma GH)
- DSIP = acute CNS; Ipamorelin = pulsatile hormone
- Plasma Half-Life
- <15 minutes
- ~2 hours
- DSIP's CNS effects outlast plasma presence
- Dosing Frequency
- Once nightly or pre-stressor
- 2–3x daily for sustained IGF-1
- DSIP = situational; Ipamorelin = chronic protocol
- Hormone Profile Impact
- No GH/cortisol/prolactin changes
- Selective GH elevation only
- Ipamorelin cleanest secretagogue profile
- Blood-Brain Barrier Penetration
- High (neuropeptide design)
- Minimal (peripheral GHS)
- DSIP reaches CNS targets; Ipamorelin doesn't
- Research Application Suitability
- Sleep studies, stress models, neuroprotection
- Sarcopenia, GH deficiency, anabolic signaling
- Choose based on biological system of interest